Pharma Industrial India’s Post

The #InflationReductionAct, enacted last year, was designed to alleviate patient and government expenses related to costly drugs. Industry players believe the #IRA inadvertently impacts the development of medications for #rarediseases and #smallmolecule medicines. The law has many benefits for Medicare patients with measures like a cap on out-of-pocket #prescriptioncosts and #insulin payments. However, it is possible that certain provisions ultimately may discourage research into drugs for rare conditions and disadvantage small molecule medicines used for treating #neurologicaldisorders and #cancers. Although the IRA primarily impacts #Medicare, because it is a critical payer #biotechs and industry leaders believe it will have significant ripples. The full impact on #drugdevelopment for rare diseases and small molecule medicines is yet to be quantified. However, fostering and incentivizing research that addresses critical patient needs must remain a priority for both industry players and policy makers.

Drug shortages have been increasing for over 20 years and are nearing record levels, both in the United Sates and Europe. When this happens with drugs like carboplatin or cisplatin, two critical chemotherapy drugs that are the backbone for different regimens to treat a number of types of cancers, the impact on health systems, healthcare professionals and patients can be especially severe. All stakeholders involved should act in a more targeted and transparent manner to prevent and mitigate drug shortages, building a safe and stable capacity to absorb changes in demand or reductions in supply. Healthcare authorities cannot manufacture drugs, but they can develop legislative, regulatory and financial remedies to create a fair and viable environment for drug manufacturers, motivating them to manufacture those critical drugs with a higher risk of shortage. #drugshortages #healthcareadministration #drugmanufacturers #mitigationstrategies

The new generation of #weightlossdrugs has the potential to help reduce prevalence of #obesity and #Type2diabetes, two of the most prevalent chronic conditions. In a new blog, Lisa Goldstein discusses the potential of the new class of glucagon-like peptide-1 (GLP-1) drugs in treating these and potentially other chronic conditions. She also considers the impact that #GLP1drugs and other pharmaceuticals currently in development could have on hospital and health system operations, as well as capital and financial planning. #healthcaremanagement https://lnkd.in/gfuUJFMe

When it comes to GLP-1s... Now is the time to start thinking about what the impacts of this new generation of drugs might be. Over the longer term, capital and financial planning will need to balance the competing themes of shifting volumes, revenue impacts, and the healthcare needs of an aging population that these drugs—and other pharmaceuticals currently in development—might introduce.

🌐 Breaking News in the Pharma Industry: Government Approves 4 Home-Grown, Affordable Drugs for Rare Diseases! The Indian government has just given the green light to four home-grown drugs designed to tackle rare diseases at more affordable prices. This marks a significant stride towards making healthcare more accessible and inclusive. > Key Takeaways: Indigenous Innovation: These approved drugs showcase the prowess of our home-grown pharmaceutical industry, demonstrating innovation and efficacy in addressing rare diseases. Affordability Matters: The approval of cheaper alternatives is a game-changer, ensuring that those affected by rare diseases can access the treatment they need without financial strain. Government's Commitment: This move reflects the government's commitment to prioritizing health and making essential medications available to a wider population. Impact Beyond Borders: The significance of this decision goes beyond national borders. It sets an inspiring example for other nations to prioritize affordable healthcare solutions and foster innovation within their own pharmaceutical sectors. Celebrating Progress: Let's take a moment to celebrate the collaborative efforts of the pharma industry, policymakers, and healthcare professionals who have worked tirelessly to bring these solutions to light. Their dedication is a testament to the power of collective action in advancing healthcare for all. Your Thoughts? I'm eager to hear your thoughts on this groundbreaking development. Read the article here: https://lnkd.in/drdzUGuP #pharmaceuticalindustry #pharmaindustry #pharma #drugs

Australia is ramping up its Authorized Prescriber Scheme for #psychedelic medicines, presenting a significant opportunity for Canadian biotechnology firms to supply it with safe and standardized good manufacturing practice-grade substances.  The Australian organization responsible for the regulation of therapeutic goods including drugs and medical devices, the Therapeutic Goods Administration (TGA), last year changed the classification of psilocybin and MDMA within the country’s Poisons Scheme to allow for them to be prescribed by authorized psychiatrists. For this purpose, they are considered Schedule 8 Controlled Drugs but for all other purposes remain Schedule 9 Prohibited Substances. Since July 1, 2023, specially authorized psychiatrists have been able to prescribe psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder. More at #Proactive #ProactiveInvestors #NEO #OTCQB #FH #FLHLF http://ow.ly/3GtZ105e49Y

95% of the 10,000 distinct #rarediseases still lack approved treatment options, highlighting an urgent unmet medical need for #orphan products. Pave the way forward for more orphan drug breakthroughs with key #regulatory strategies that can ensure early market entry and optimal patient access to life-saving treatments. Read more here: https://bit.ly/3PCSbQM Authors: Sherry, Xueying WANG (PhD, MBA) - Radhika Singla - See Jessica - Seok Hwan Lim #strategy #marketaccess #APAC

Discover how early regulatory strategy planning can ensure #early market access and optimal patient access for #orphandrugs drugs. Our latest blog delves into the obstacles faced by companies while developing orphan drugs and highlights strategies that are particularly pertinent for pharmaceutical companies considering launching drug products for #raredisease diseases.